Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 26 Apr 2023
Once a woman turns 40, experts advise that she at the very least think about starting a breast cancer screening program. According to a recent study, Black women need this advice above all others.
Read Full NewsComplicated eligibility rules, stigma surrounding smoking and lung cancer, and confusion about the screening process continue to keep many high-risk patients from getting screened.
A recent post hoc analysis assesses whether PSA changes can predict survival outcomes in patients with metastatic or very high risk nonmetastatic prostate cancer.
The FDA says the increased risk of hematologic secondary primary malignancies with tazemetostat now outweighs the benefits of the drug; Ipsen pulls it from the market.
The BCL-2 inhibitor was granted accelerated approval based on findings from the phase 1/2 BGB-11417-201 study.
1.
More Support for Early Detection; Cancer in Men Rising; Diet Drives Colon Cancer
2.
Chemo-Free Quadruplet Shows Promise as DLBCL's First Therapy.
3.
The White House has postponed its plan to outlaw menthol cigarettes indefinitely.
4.
New CAR-T Drug Induces Durable Remissions in ALL, Published Data Show
5.
According to research, the mineralization of the bone matrix controls the growth of tumor cells.
1.
Angina Haemorrhagica Bullosa: What You Need to Know
2.
Essential Oncology Updates: Diagnosis, Treatment Advances, Tools & Education Resources
3.
Exploring the Role of Fecal Leukocytes in Intestinal Health
4.
Innovative Strategies in Prostate Cancer Management: From Surveillance to Systemic Therapies
5.
HIPEC in Platinum-Sensitive Ovarian Cancer: A Promising Yet Controversial Option
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part III
2.
Navigating the Complexities of Ph Negative ALL - Part X
3.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part III
4.
Experts' Opinion on the Goal of Treatment of Patients with Relapsed Adult B-cell ALL
5.
Navigating the Complexities of Ph Negative ALL - Part III
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge